About XTL Biopharmaceuticals
XTL Biopharmaceuticals is a company founded in 1993.. XTL Biopharmaceuticals has raised $1 million across 5 funding rounds from investors including Challenge Fund - Etgar. The company has 11 employees as of December 31, 2024. XTL Biopharmaceuticals has completed 1 acquisition, including The SocialProxies. XTL Biopharmaceuticals offers products and services including Pharmaceutical Development Services.
- Employees 11 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Xtl Biopharmaceuticals Ltd.
-
Annual Revenue
$457.96 K (USD)0as on Dec 31, 2024
-
Net Profit
$-1.04 M (USD)42.15as on Dec 31, 2024
-
EBITDA
$-2 M (USD)-158.86as on Dec 31, 2024
-
Total Equity Funding
$1 M (USD)
in 5 rounds
-
Latest Funding Round
$1.5 M (USD), Post-IPO
Aug 14, 2024
- Investors
-
Employee Count
11
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of XTL Biopharmaceuticals
XTL Biopharmaceuticals is a publicly listed company on the TASE with ticker symbol XTLB in Israel, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of XTL Biopharmaceuticals
XTL Biopharmaceuticals offers a comprehensive portfolio of products and services, including Pharmaceutical Development Services. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Acquisition and development of late-stage pharmaceutical candidates for clinical needs
Unlock access to complete
Unlock access to complete
Funding Insights of XTL Biopharmaceuticals
XTL Biopharmaceuticals has successfully raised a total of $1M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $1.5 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Post-IPO — $1.5M
-
First Round
First Round
(20 May 2002)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2024 | Amount | Post-IPO - XTL Biopharmaceuticals | Valuation |
investors |
|
| Mar, 2017 | Amount | Post-IPO - XTL Biopharmaceuticals | Valuation |
investors |
|
| Feb, 2017 | Amount | Post-IPO - XTL Biopharmaceuticals | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in XTL Biopharmaceuticals
XTL Biopharmaceuticals has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Challenge Fund - Etgar. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by XTL Biopharmaceuticals
XTL Biopharmaceuticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include The SocialProxies. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Cloud-based proxy services are offered for secure network access.
|
2019 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - XTL Biopharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Xtl Biopharmaceuticals Comparisons
Competitors of XTL Biopharmaceuticals
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Xtl Biopharmaceuticals
Frequently Asked Questions about XTL Biopharmaceuticals
When was XTL Biopharmaceuticals founded?
XTL Biopharmaceuticals was founded in 1993 and raised its 1st funding round 9 years after it was founded.
Is XTL Biopharmaceuticals a funded company?
XTL Biopharmaceuticals is a funded company, having raised a total of $1M across 5 funding rounds to date. The company's 1st funding round was a Post-IPO of $2.5M, raised on May 20, 2002.
How many employees does XTL Biopharmaceuticals have?
As of Dec 31, 2024, the latest employee count at XTL Biopharmaceuticals is 11.
What is the annual revenue of XTL Biopharmaceuticals?
Annual revenue of XTL Biopharmaceuticals is $457.96K as on Dec 31, 2024.
What does XTL Biopharmaceuticals do?
XTL Biopharmaceuticals was founded in 1993 within the biopharmaceutical sector. Late-stage product candidates are acquired and advanced to meet unmet clinical needs in inflammatory conditions. Clinical trials are conducted for hCDR1 peptide in Phase 2 targeting systemic lupus erythematosus, and recombinant erythropoietin in Phase 1 aimed at extending survival for advanced multiple myeloma patients. Operations center on therapeutic development without specified geographic focus.
What products or services does XTL Biopharmaceuticals offer?
XTL Biopharmaceuticals offers Pharmaceutical Development Services.
Is XTL Biopharmaceuticals publicly traded?
Yes, XTL Biopharmaceuticals is publicly traded on TASE under the ticker symbol XTLB.
How many acquisitions has XTL Biopharmaceuticals made?
XTL Biopharmaceuticals has made 1 acquisition, including The SocialProxies.
Who are XTL Biopharmaceuticals's investors?
XTL Biopharmaceuticals has 1 investor. Key investors include Challenge Fund - Etgar.
What is XTL Biopharmaceuticals's ticker symbol?
The ticker symbol of XTL Biopharmaceuticals is XTLB on TASE.